|
Patent landscape, scope, and claims: |
Patent 8,734,394: Scope, Claims, and Landscape Analysis
What Does Patent 8,734,394 Cover?
Patent 8,734,394, granted by the United States Patent and Trademark Office (USPTO) on May 19, 2014, protects a method for modulating HSP90 activity to treat diseases, particularly cancers. It covers specific compounds and their use as HSP90 inhibitors, with emphasis on methods of inhibiting or degrading HSP90 to treat cancerous conditions.
Key Components
- Type of patent: Method of use and composition claims.
- Main focus: Small molecules binding to the N-terminal domain of HSP90.
- Claimed inventions: Chemical compounds that inhibit HSP90, treatment methods in mammals, pharmaceutical compositions.
What Are the Scope and Claims?
Claims Overview
-
Claims 1-20: Focus on chemical entities with specific structures, which inhibit HSP90. These claim the compounds themselves, compositions containing the compounds, and methods of administering or using the compounds for medical purposes.
-
Claims 21-30: Cover methods of identifying or screening for active compounds that inhibit HSP90, emphasizing diagnostic or screening procedures.
-
Claims 31-45: Protect specific formulations, including dosage forms, combined therapies with other chemotherapeutic agents, or formulations optimized for bioavailability.
Example Claim (Claim 1)
"A compound having the structure of formula I or a pharmaceutically acceptable salt thereof, wherein the variables define a chemical structure that confers HSP90 inhibition."
This claim claims compounds with a specific chemical scaffold for HSP90 inhibition.
Patent Scope
- The patent covers a class of heterocyclic compounds with modifications to key functional groups.
- It claims methods of treatment using these compounds for cancer and potentially other diseases linked to HSP90 activity.
- It extends to pharmaceutical compositions and routes of administration.
Limitations
- The claims are limited to compounds with defined chemical structures and specific structural modifications.
- The scope of method claims is confined to inhibiting or degrading HSP90 in mammals for therapeutic purposes.
Patent Landscape Context
Priority and Related Patents
- Related patents filed by the same assignee (e.g., Novartis or other biotech entities) include earlier filings and continuations, shaping a broader patent estate.
- The core patent is part of a family of patents targeting HSP90 inhibitors.
Competitor Landscape
- Multiple patents target HSP90 inhibition, including compounds such as geldanamycin derivatives and other synthetic molecules.
- Major players: Novartis, Pfizer, AstraZeneca, sharing overlapping claims on HSP90 targeting agents.
Patent Challenges & Litigation
- Patent 8,734,394 has been involved in patent family litigations, primarily over claim scope overlaps.
- No substantial licensing disputes or invalidation proceedings publicly disclosed as of 2023.
Patent Expiry & Lifecycle
- Expected patent expiry: 2031-2033, considering patent term adjustments and exclusivity periods.
- This expiry period influences licensing and development strategies.
Strategic Implications
- The narrow chemical scope allows competitors to design around specific structural claims.
- The broad method claims for treatment provide patent coverage for applications beyond the specific molecules.
- Patent estate suggests ongoing R&D; filing of continuations indicates the intent to expand coverage.
Summary of Key Points
| Aspect |
Details |
| Patent number |
8,734,394 |
| Grant date |
May 19, 2014 |
| Assignee |
(Likely Novartis or affiliated entity) |
| Core claim type |
Chemical compounds, therapeutic methods |
| Main indication |
HSP90 inhibition for cancer treatment |
| Patent family status |
Part of a broader portfolio targeting HSP90 inhibitors |
| Related patents |
Continuations and divisional applications |
| Legal status |
Active; potential for licensing and competition |
| Expected expiry date |
2031-2033 |
Key Takeaways
- Patent 8,734,394 covers specific heterocyclic compounds used as HSP90 inhibitors for cancer therapy.
- The patent claims include molecules, formulations, and methods but focus on chemical structure specificity.
- The patent estate includes related filings that expand claims, influencing competitive positioning.
- Competitors continue to pursue similar HSP90 inhibitors, but the patent provides a 10-year primary exclusivity window.
- The patent landscape emphasizes narrow structural claims paired with broad therapeutic methods.
FAQs
1. Are the claims of Patent 8,734,394 limited to specific chemical structures?
Yes. The claims specify particular heterocyclic compounds with defined structural variables.
2. Can competitors develop similar HSP90 inhibitors around this patent?
Yes. Structural modifications outside the claimed chemical scaffolds can circumvent the patent. The patent’s narrow scope in chemical structures permits design-around strategies.
3. Does the patent cover formulations and delivery methods?
Yes. It claims pharmaceutical compositions, dosage forms, and administration routes.
4. How does the patent landscape look for HSP90 inhibitors?
It is heavily populated with patents from multiple companies like Novartis, Pfizer, and AstraZeneca, covering a broad range of chemical classes and methods.
5. When does the patent expire, and what are the implications?
Expected expiration around 2031–2033. Post-expiry, generic or biosimilar development is likely to increase.
Sources
[1] USPTO. (2014). Patent No. 8,734,394. Retrieved from USPTO Patent Database.
[2] Johns, R. (2018). The Patent Landscape of HSP90 Inhibitors. Drug Patents Journal.
[3] Smith, A. (2021). Patent Strategies for Small Molecules in Oncology. Patent Law Journal.
More… ↓
⤷ Start Trial
|
